Cargando…

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule

Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from...

Descripción completa

Detalles Bibliográficos
Autores principales: Afra, T. P., Razmi, T Muhammed, Dogra, Sunil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362739/
https://www.ncbi.nlm.nih.gov/pubmed/30775293
http://dx.doi.org/10.4103/idoj.IDOJ_437_18
_version_ 1783392989136027648
author Afra, T. P.
Razmi, T Muhammed
Dogra, Sunil
author_facet Afra, T. P.
Razmi, T Muhammed
Dogra, Sunil
author_sort Afra, T. P.
collection PubMed
description Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses. Being a relatively new drug in the treatment armamentarium of psoriasis and other inflammatory dermatoses; in this review, we will discuss various practical aspects of prescribing oral apremilast, based on the current and emerging literature.
format Online
Article
Text
id pubmed-6362739
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-63627392019-02-17 Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule Afra, T. P. Razmi, T Muhammed Dogra, Sunil Indian Dermatol Online J Review Article Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses. Being a relatively new drug in the treatment armamentarium of psoriasis and other inflammatory dermatoses; in this review, we will discuss various practical aspects of prescribing oral apremilast, based on the current and emerging literature. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6362739/ /pubmed/30775293 http://dx.doi.org/10.4103/idoj.IDOJ_437_18 Text en Copyright: © 2019 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Afra, T. P.
Razmi, T Muhammed
Dogra, Sunil
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
title Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
title_full Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
title_fullStr Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
title_full_unstemmed Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
title_short Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
title_sort apremilast in psoriasis and beyond: big hopes on a small molecule
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362739/
https://www.ncbi.nlm.nih.gov/pubmed/30775293
http://dx.doi.org/10.4103/idoj.IDOJ_437_18
work_keys_str_mv AT afratp apremilastinpsoriasisandbeyondbighopesonasmallmolecule
AT razmitmuhammed apremilastinpsoriasisandbeyondbighopesonasmallmolecule
AT dograsunil apremilastinpsoriasisandbeyondbighopesonasmallmolecule